Radiographic progression in patients with ankylosing spondylitis after 2 years of treatment with the tumour necrosis factor alpha antibody infliximab.
about
Comparison of performance of the Assessment of SpondyloArthritis International Society, the European Spondyloarthropathy Study Group and the modified New York criteria in a cohort of Chinese patients with spondyloarthritisEfficacy of infliximab on MRI-determined bone oedema in psoriatic arthritisSpanish Rheumatology Society and Hospital Pharmacy Society Consensus on recommendations for biologics optimization in patients with rheumatoid arthritis, ankylosing spondylitis and psoriatic arthritisThe cost-effectiveness of infliximab in the treatment of ankylosing spondylitis in Spain. Comparison of clinical trial and clinical practice data.First signs and symptoms of spondyloarthritis--data from an inception cohort with a disease course of two years or less (REGISPONSER-Early)The use of tumour necrosis factor alpha-blockers in daily routine. An Austrian consensus project.Ankylosis in ankylosing spondylitis: current concepts.Tumor necrosis factor-α signaling in macrophages.Spinal radiographic progression in patients with ankylosing spondylitis treated with TNF-α blocking therapy: a prospective longitudinal observational cohort study.ASAS/EULAR recommendations for the management of ankylosing spondylitis.Progression of radiographic damage in patients with ankylosing spondylitis: defining the central role of syndesmophytes.Evaluation of dose reduction versus standard dosing for maintenance of remission in patients with spondyloarthritis and clinical remission with anti-TNF (REDES-TNF): study protocol for a randomized controlled trialAnti-TNF Therapy in Ankylosing Spondylitis: Insights for the ClinicianAnkylosing spondylitis: recent breakthroughs in diagnosis and treatmentThe effect of three years of TNFα blocking therapy on markers of bone turnover and their predictive value for treatment discontinuation in patients with ankylosing spondylitis: a prospective longitudinal observational cohort study.Pharmacological management of undifferentiated spondyloarthropathies.Developments and current pharmacotherapeutic recommendations for ankylosing spondylitis.Early diagnosis of spondyloarthritis.Sleep disturbances are associated with increased pain, disease activity, depression, and anxiety in ankylosing spondylitis: a case-control studyLow sclerostin levels: a predictive marker of persistent inflammation in ankylosing spondylitis during anti-tumor necrosis factor therapy?Review article: Altering the natural history of Crohn's disease--evidence for and against current therapies.Inflammatory biomarkers, disease activity and spinal disease measures in patients with ankylosing spondylitis after treatment with infliximabSerum amyloid a as a useful indicator of disease activity in patients with ankylosing spondylitis.Infliximab in the treatment of ankylosing spondylitis.Anti-TNF-alpha therapy with infliximab in spondyloarthritides.Structural damage in rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis: traditional views, novel insights gained from TNF blockade, and concepts for the future.First update of the current evidence for the management of ankylosing spondylitis with non-pharmacological treatment and non-biologic drugs: a systematic literature review for the ASAS/EULAR management recommendations in ankylosing spondylitis.Biologic therapies for spondyloarthritis: what is new?Impact of biological therapy on spondyloarthritis.Anti-TNFs in axial spondyloarthritis.EULAR recommendations for the use of imaging in the diagnosis and management of spondyloarthritis in clinical practice.Construct validity of clinical spinal mobility tests in ankylosing spondylitis: a systematic review and meta-analysis.Baseline increased 18F-fluoride uptake lesions at vertebral corners on positron emission tomography predict new syndesmophyte development in ankylosing spondylitis: a 2-year longitudinal study.Bioboosters in the treatment of rheumatic diseases: a comprehensive review of currently available biologics in patients with rheumatoid arthritis, ankylosing spondylitis and psoriatic arthritis.Reduction in Spinal Radiographic Progression in Ankylosing Spondylitis Patients Receiving Prolonged Treatment With Tumor Necrosis Factor Inhibitors.The relationship between inflammation and new bone formation in patients with ankylosing spondylitis.Relationship between serum adipokine levels and radiographic progression in patients with ankylosing spondylitis: A preliminary 2-year longitudinal study.Opinion: Perspectives on imaging in axial spondyloarthritis.Comparison of the cost-effectiveness of infliximab in the treatment of ankylosing spondylitis in the United Kingdom based on two different clinical trials.Ankylosing spondylitis in Ireland: patient access and response to TNF-α blockers.
P2860
Q24604766-B878AD9F-9600-43F9-9796-B9A025004253Q24674877-16AEA996-76D0-43AA-BD20-D62A76E09A04Q26852081-28C516E7-DE2F-4808-9723-2C99114DA23FQ31142567-9F98D3C6-D87C-49CF-AB17-A013902B0A1DQ33408102-9C7D45CA-899E-42C2-BF0A-8458AAA0DA30Q33554356-1CF2ABFA-B635-4ABE-A673-808C83A7FFAFQ34474761-1F1130FB-8CDD-491C-8337-BA715950E3E8Q34734335-8E01830B-83B1-4AFD-BAAC-B3745AAB17E7Q35449032-AB95BAFC-B603-4856-A17C-DBF43424B692Q35637012-C5908DEB-3E79-4C62-8EAA-C4DF4E40510EQ35954535-1BD402A5-3DAA-464D-9702-ABCEF44ED6BCQ35986462-D6A86A6E-B2E8-4BE2-95A3-52CE95466F9EQ36059338-DBB270D1-2BA0-44C2-AAFA-83110D27218DQ36143588-39F37465-8C76-4EA9-90FC-C9B968A1DB71Q36245903-E6370D54-728C-4B61-9759-9B4B84EDA84FQ36349645-5B755E5D-B337-4AF4-AB04-D31109701F56Q36458447-276322B1-C725-4EB7-A456-E6AE1C61946FQ36611042-40C3918A-20EE-4DA3-ACE9-7818FC8BFE04Q36633200-EA2E2B39-2261-4652-81B7-9024BE07C864Q36633205-7B720046-40A9-4EED-939F-8AC32980836CQ36710319-2A74ADB8-3743-46C6-9612-865FECA52951Q36930591-89E1A099-AA79-4145-B23E-66219981FF70Q37065490-48970B67-D035-42E8-9518-8E119BA15D2BQ37290474-D50E623A-0A32-4A06-8A06-6286ACAA8823Q37729028-C0975C8C-0923-4057-AD95-C51EEC85F4BFQ37882064-C48F3188-E355-4C35-9716-FA4B5EE4B4D9Q38003531-9CD6E41B-B12A-4369-89A3-B4305BFC2FB0Q38031436-46D092A4-4D32-4517-A2CD-65CA6EC7ECA3Q38218614-B52E35A6-A1DF-4E8B-9858-76432760F818Q38311916-6B2941BD-C7C7-45AC-9578-35AF3CF6D6B8Q38402703-09D64CD0-980F-4F5A-84BE-97FF215F273FQ38580198-E15937BE-2D18-46B7-AFBC-F75FFC0A37FBQ38762450-B5902BC1-8A8D-459A-8FD4-A043663C0569Q38993250-A1A96A78-F56A-4E88-93C1-CEF16AF0B39DQ39328132-636BF56B-408F-4E43-BD19-797A944D4921Q41396084-E5F48BE6-A3CB-444F-B519-C6C474C22775Q41521787-3D18557D-2433-474C-96E0-E51D702ADD8CQ42604065-EBC5ED86-343C-40D0-84C2-4FD576302861Q42624096-23D70FA7-9AC7-40C3-9397-F733798FE5F7Q44659462-E373BBCD-7478-42C0-8DA9-E73808192904
P2860
Radiographic progression in patients with ankylosing spondylitis after 2 years of treatment with the tumour necrosis factor alpha antibody infliximab.
description
2005 nî lūn-bûn
@nan
2005年の論文
@ja
2005年論文
@yue
2005年論文
@zh-hant
2005年論文
@zh-hk
2005年論文
@zh-mo
2005年論文
@zh-tw
2005年论文
@wuu
2005年论文
@zh
2005年论文
@zh-cn
name
Radiographic progression in pa ...... tor alpha antibody infliximab.
@ast
Radiographic progression in pa ...... tor alpha antibody infliximab.
@en
type
label
Radiographic progression in pa ...... tor alpha antibody infliximab.
@ast
Radiographic progression in pa ...... tor alpha antibody infliximab.
@en
prefLabel
Radiographic progression in pa ...... tor alpha antibody infliximab.
@ast
Radiographic progression in pa ...... tor alpha antibody infliximab.
@en
P2093
P2860
P356
P1476
Radiographic progression in pa ...... tor alpha antibody infliximab.
@en
P2093
P2860
P304
P356
10.1136/ARD.2004.033472
P407
P577
2005-03-18T00:00:00Z